SEARCH

SEARCH BY CITATION

References

  • 1
    El-Serag HB, Mason AC. Increasing incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745750.
  • 2
    El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33:6265.
  • 3
    Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(Suppl 1):34S38S.
  • 4
    El-Serag HB. Global epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5:87107.
  • 5
    Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519524.
  • 6
    Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Haematol Oncol 1992; 14:117128.
  • 7
    Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985; 1:13571360.
  • 8
    Lok ASF, Lai C-L. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9:110115.
  • 9
    Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432438.
  • 10
    DiBisceglie AM, Hoofnagle JH. Elevations of serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64:21172120.
  • 11
    Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19:6166.
  • 12
    Colombo M, DeFranchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675679.
  • 13
    Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20:6571.
  • 14
    Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78:977985.
  • 15
    Sheu JC, Sung JL, Chen DS, Lai MY, Wang TH, Yu JY, Yang PM, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56:660666.
  • 16
    Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M. Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour Biol 1990; 11:319326.
  • 17
    Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 1989; 49:64936497.
  • 18
    Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990; 11:481488.
  • 19
    Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Palareti G, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma with special reference to the des-gamma-carboxyprothrombin. Liver Transpl Surg 1995; 1:249255.
  • 20
    Takikawa Y, Suzuki K, Yamazaki K, Goto T, Madarame T, Miura Y, Yoshida T, et al. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma. J Gastroenterol Hepatol 1992; 7:16.
  • 21
    Fujiyama S, Izuno K, Yamasaki K, Sato T, Taketa K. Determination of optimum cutoff levels of plasma des-gamma carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristics curves. Tumour Biol 1992; 13:316323.
  • 22
    Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95:10361040.
  • 23
    Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993; 38:21702176.
  • 24
    Mita Y, Aoyagi Y, Yanagi M, Suda T, Sizuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82:16431648.
  • 25
    Nakagawa T, Seki T, Shiro T, Wakabayashi M, Imamura M, Itoh T, Tamai T, et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol 1999; 14:281286.
  • 26
    Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Galluci A, Palareti G, Gozzetti G. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxyprothrombin. Liver Transplant Surg 1995; 4:249255.
  • 27
    Brunello F, Marcarino C, Pasquero P, Gastaldi P, Gonella S, Martini S, Calcamuggi G, et al. The des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma. Ital J Gastroenterol 1993; 25:912.
  • 28
    Wallis Marsh J, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM Staging systems for patients with hepatoma predictive of outcome? Cancer 2000; 88:538543.
  • 29
    Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research, 4th ed. Oxford: Blackwell Science, 2002.
  • 30
    Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1998; 8:283298.
  • 31
    Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures. Ann Intern Med 1981; 94:555600.
  • 32
    Sullivan-Pepe M, Thompson M. Combining diagnostic test results to increase accuracy. Biostatistics 2000; 1:123140.
  • 33
    Okuda H, Nakanishi T, Kazuko T, Saito A, Hayashi K, Takasaki K, Takenami K, et al. Serum levels of des—carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma Cancer 2000; 88:544549.
  • 34
    Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62:S57S63.
  • 35
    Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, Itano S, Ono N, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000; 7:249256.
  • 36
    Lai CL, Lam KC, Wong KP, Wu PC, Todd D. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer 1981; 47:27462755.
  • 37
    Shimokawa Y, Okuda K, Kubo Y, Kaneko A, Arishima T, Nagata E, Hashimoto M, et al. Serum glutamic oxalacetic transaminases/glutamic pyruvic transaminases ratios in hepatocellular carcinoma. Cancer 1977; 40:319324.
  • 38
    Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36:140147.
  • 39
    Brunello F, Marcarino C, Pasquero P, Gastaldi P, Gonella S, Martini S, Calcamuggi G, et al. The des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma. Ital J Gastroenterol 1993; 25:912.
  • 40
    Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27:273.
  • 41
    Ohhira M, Saito H, Suzuki Y, Naraki T, Sakurai S, Ohtake T, Suzuki M, et al. A variant of des-gamma-carboxy prothrombin was increased in alcoholic liver disease without hepatocellular carcinoma. Alcohol Clin Exp Res 2001; 25:46S50S.
  • 42
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christiensen, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421430.
  • 43
    Sakon M, Monden M, Gotoh M, Kobayashi K, Kanai T, Umeshita K, Endoh W, et al. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Am J Gastroenterol 1991; 86:339345.
  • 44
    Sullivan-Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93:10541061.